Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis

Winter J. Gibbs, Tracy Hagemann

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for purified poloxamer 188, a product in Phase III trials. DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966-November 2003), International Pharmaceutical Abstracts (1970-November 2003), and the Cochrane Library Database (3rd quarter 2003). Key search terms included purified poloxamer 188, Flocor, CRL-5861, poloxamer 188, RheothRx, and pluronic F-68. STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, adverse effects, and pharmacokinetics were obtained from randomized, open-label, and blinded clinical trials. Toxicology data were obtained from unpublished studies with purified poloxamer 188 and from available data on poloxamer 188 (nonpurified form). DATA SYNTHESIS: Purified poloxamer 188 is a highly purified form of the nonionic block copolymer poloxamer 188. It lowers blood viscosity, decreases red blood cell (RBC) aggregation, and decreases friction between RBCs and vessel walls to increase microvascular blood flow and decrease cell injury. In clinical trials, purified poloxamer 188 demonstrated safety, but little efficacy for the treatment of sickle cell vaso-occlusive crisis. Increased efficacy has been shown in patients on concurrent hydroxyurea therapy and those <15 years of age. CONCLUSIONS: Purified poloxamer 188 represents a new approach to the management of the sickle cell vaso-occlusive crisis. Children and patients on hydroxyurea may benefit most from purified poloxamer 188 therapy. Further studies are needed to confirm its efficacy and to determine whether the drug decreases sickle cell disease severity and complications.

Original languageEnglish (US)
Pages (from-to)320-324
Number of pages5
JournalAnnals of Pharmacotherapy
Volume38
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Poloxamer
Hydroxyurea
Toxicology
Pharmacokinetics
Clinical Trials
Databases
Cell Aggregation
Blood Viscosity
Friction
Sickle Cell Anemia
Drug Interactions
MEDLINE
Pharmaceutical Preparations
Libraries
Language
Erythrocytes
Pharmacology

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis. / Gibbs, Winter J.; Hagemann, Tracy.

In: Annals of Pharmacotherapy, Vol. 38, No. 2, 01.02.2004, p. 320-324.

Research output: Contribution to journalReview article

@article{cff833f63e9c47a68c7ae5ef256d0e75,
title = "Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis",
abstract = "OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for purified poloxamer 188, a product in Phase III trials. DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966-November 2003), International Pharmaceutical Abstracts (1970-November 2003), and the Cochrane Library Database (3rd quarter 2003). Key search terms included purified poloxamer 188, Flocor, CRL-5861, poloxamer 188, RheothRx, and pluronic F-68. STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, adverse effects, and pharmacokinetics were obtained from randomized, open-label, and blinded clinical trials. Toxicology data were obtained from unpublished studies with purified poloxamer 188 and from available data on poloxamer 188 (nonpurified form). DATA SYNTHESIS: Purified poloxamer 188 is a highly purified form of the nonionic block copolymer poloxamer 188. It lowers blood viscosity, decreases red blood cell (RBC) aggregation, and decreases friction between RBCs and vessel walls to increase microvascular blood flow and decrease cell injury. In clinical trials, purified poloxamer 188 demonstrated safety, but little efficacy for the treatment of sickle cell vaso-occlusive crisis. Increased efficacy has been shown in patients on concurrent hydroxyurea therapy and those <15 years of age. CONCLUSIONS: Purified poloxamer 188 represents a new approach to the management of the sickle cell vaso-occlusive crisis. Children and patients on hydroxyurea may benefit most from purified poloxamer 188 therapy. Further studies are needed to confirm its efficacy and to determine whether the drug decreases sickle cell disease severity and complications.",
author = "Gibbs, {Winter J.} and Tracy Hagemann",
year = "2004",
month = "2",
day = "1",
doi = "10.1345/aph.1D223",
language = "English (US)",
volume = "38",
pages = "320--324",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "2",

}

TY - JOUR

T1 - Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis

AU - Gibbs, Winter J.

AU - Hagemann, Tracy

PY - 2004/2/1

Y1 - 2004/2/1

N2 - OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for purified poloxamer 188, a product in Phase III trials. DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966-November 2003), International Pharmaceutical Abstracts (1970-November 2003), and the Cochrane Library Database (3rd quarter 2003). Key search terms included purified poloxamer 188, Flocor, CRL-5861, poloxamer 188, RheothRx, and pluronic F-68. STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, adverse effects, and pharmacokinetics were obtained from randomized, open-label, and blinded clinical trials. Toxicology data were obtained from unpublished studies with purified poloxamer 188 and from available data on poloxamer 188 (nonpurified form). DATA SYNTHESIS: Purified poloxamer 188 is a highly purified form of the nonionic block copolymer poloxamer 188. It lowers blood viscosity, decreases red blood cell (RBC) aggregation, and decreases friction between RBCs and vessel walls to increase microvascular blood flow and decrease cell injury. In clinical trials, purified poloxamer 188 demonstrated safety, but little efficacy for the treatment of sickle cell vaso-occlusive crisis. Increased efficacy has been shown in patients on concurrent hydroxyurea therapy and those <15 years of age. CONCLUSIONS: Purified poloxamer 188 represents a new approach to the management of the sickle cell vaso-occlusive crisis. Children and patients on hydroxyurea may benefit most from purified poloxamer 188 therapy. Further studies are needed to confirm its efficacy and to determine whether the drug decreases sickle cell disease severity and complications.

AB - OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for purified poloxamer 188, a product in Phase III trials. DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966-November 2003), International Pharmaceutical Abstracts (1970-November 2003), and the Cochrane Library Database (3rd quarter 2003). Key search terms included purified poloxamer 188, Flocor, CRL-5861, poloxamer 188, RheothRx, and pluronic F-68. STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, adverse effects, and pharmacokinetics were obtained from randomized, open-label, and blinded clinical trials. Toxicology data were obtained from unpublished studies with purified poloxamer 188 and from available data on poloxamer 188 (nonpurified form). DATA SYNTHESIS: Purified poloxamer 188 is a highly purified form of the nonionic block copolymer poloxamer 188. It lowers blood viscosity, decreases red blood cell (RBC) aggregation, and decreases friction between RBCs and vessel walls to increase microvascular blood flow and decrease cell injury. In clinical trials, purified poloxamer 188 demonstrated safety, but little efficacy for the treatment of sickle cell vaso-occlusive crisis. Increased efficacy has been shown in patients on concurrent hydroxyurea therapy and those <15 years of age. CONCLUSIONS: Purified poloxamer 188 represents a new approach to the management of the sickle cell vaso-occlusive crisis. Children and patients on hydroxyurea may benefit most from purified poloxamer 188 therapy. Further studies are needed to confirm its efficacy and to determine whether the drug decreases sickle cell disease severity and complications.

UR - http://www.scopus.com/inward/record.url?scp=1642458264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642458264&partnerID=8YFLogxK

U2 - 10.1345/aph.1D223

DO - 10.1345/aph.1D223

M3 - Review article

VL - 38

SP - 320

EP - 324

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 2

ER -